Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of HU6

NCT05433506
View directory record Official record
Conditions
Obese
Interventions
HU6 Tablet, HU6 Capsule
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT03327558
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Naproxen Capsules to Treat Dental Pain

NCT01229228
View directory record Official record
Conditions
Dental Pain
Interventions
Naproxen Test, Naprosyn, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 18, 2026, 4:05 PM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

NCT00160199
View directory record Official record
Conditions
Secondary Amenorrhea
Interventions
PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
42
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study

NCT01602887
View directory record Official record
Conditions
Healthy
Interventions
PD-0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Calcium Supplementation in Postmenopausal Women

NCT00172172
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH/Calcium, PTH/placebo, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 18, 2026, 4:05 PM EDT
Completed No phase listed Observational

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

NCT02425228
View directory record Official record
Conditions
Elevated PSA, Prostate Cancer
Interventions
Targeted biopsy
Device
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 18, 2026, 4:05 PM EDT
Not listed Phase 1 Interventional

Study of ON 123300 in Patients With Advanced Cancer

NCT04739293
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
ON123300
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Grand Rapids, Michigan • Greenville, South Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 18, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

NCT00726479
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

NCT06211179
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01704079
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 18, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

NCT00012246
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

NCT03377179
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions
ABC294640, Hydroxychloroquine Sulfate 200 MG
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

NCT07253441
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN XR (TBM), CTN SR, CTN XR (Clin)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Lenexa, Kansas • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 18, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

NCT06452160
View directory record Official record
Conditions
Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Interventions
BGC515
Drug
Lead sponsor
BridGene Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

NCT05797753
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions
SAR443820, Erythromycin ethyl succinate, Itraconazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

NCT06185985
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

NCT02685709
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 18, 2026, 4:05 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

NCT04984447
View directory record Official record
Conditions
Environmental Enteric Dysfunction
Interventions
TNIB Catheter
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 18, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age

NCT02346214
View directory record Official record
Conditions
Gestational Age
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
Up to 24 Hours
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Loma Linda, California • Iowa City, Iowa • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 18, 2026, 4:05 PM EDT